ORIC Live signaler | Maksimer profitt med Getagraph.com

KJøP 107878 min ago

@ $11.31

Utstedt: 14 feb 2024 @ 20:07

Avkastning: -24.44%

Forrige signal: feb 13 - 19:45

Forrige signal: Selg

Avkastning: -1.65 %

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 19:05):

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States...

Stats
Dagens volum	147 576
Gjennomsnittsvolum	570 877
Markedsverdi	576.12M
EPS	$0 ( 2024-03-21 )
Neste inntjeningsdato	( $-0.440 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.36
ATR14	$0.0160 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Chacko Jacob	Sell	40 000	Common Stock
2024-02-06	Chacko Jacob	Sell	13 958	Common Stock
2024-02-07	Chacko Jacob	Sell	26 042	Common Stock
2024-01-02	Multani Pratik S	Buy	180 000	Stock Option (right to buy)
2024-01-02	Multani Pratik S	Buy	30 000	Restricted Stock Unit

INSIDER POWER
54.58
Last 99 transactions
Buy: 6 373 472 \| Sell: 3 807 004

Volum Korrelasjon

Lang: 0.26 (neutral)

Kort: 0.46 (neutral)

Signal:(62.629) Neutral

Oric Pharmaceuticals Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Oric Pharmaceuticals Inc Korrelasjon - Valuta/Råvare

0.91
( very strong )

0.95
( very strong )

0.00
( neutral )

0.84
( strong )

0.79
( moderate )

-0.81
( strong negative )

Oric Pharmaceuticals Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-1.03M (0.00 %)
EPS:	$-1.960

FY	2023
Omsetning:	$0
Bruttogevinst:	$-1.03M (0.00 %)
EPS:	$-1.960

FY	2022
Omsetning:	$0
Bruttogevinst:	$-966 000 (0.00 %)
EPS:	$-2.31

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.07

Financial Reports:

No articles found.

Oric Pharmaceuticals Inc

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.